Skip to main content

This site is intended for U.S. Healthcare Professionals.

Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve.
Click here to learn how we are responding.

Storage & Handling

Orange Cap Vial Image

5 through 11 years of age,
DILUTE BEFORE USE
(Orange Cap)

Emergency uses of the vaccines have not been approved or licensed by FDA but have been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) in individuals aged 6 months and older for the Pfizer-BioNTech COVID-19 Vaccine and 5 years and older for the Pfizer-BioNTech COVID-19 Vaccine, Bivalent. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b) (1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.

STORAGE - ORANGE CAP

The 5 through 11 years, DILUTE BEFORE USE (Orange Cap) presentation may be stored in the refrigerator or in an ultra-low-temperature freezer1,5

Vials may be stored or transported at refrigerated temperatures of 2°C to 8°C (35°F to 46°F) for up to 10 weeks. Total cumulative time the vials are stored at 2°C to 8°C (35°F to 46°F) should not exceed 10 weeks. Vials may also be stored in an ultra-low-temperature freezer between -90°C to -60°C (-130°F to -76°F) for up to 9 months from the date of manufacture printed on the vial and cartons. Expiry information may be updated periodically, click here for updated expiry information.

Storage Storage
 

Vial storage prior to use - Orange Cap1

  • Cartons of the vaccine will arrive frozen at ultra-cold conditions in thermal containers with dry ice
  • Once received, frozen vials may be immediately transferred to the refrigerator [2°C to 8°C (35°F to 46°F)], thawed, and stored for up to 10 weeks
    • The 10-week refrigerated expiry date should be recorded on the carton at the time of transfer
  • Alternatively, frozen vials may be stored in an ultra-low-temperature freezer at -90°C to -60°C (-130°F to -76°F). Do not store vials at -25°C to -15°C (-13°F to 5°F). Once vials are thawed they should not be refrozen
  • If vials are received at 2°C to 8°C, they should be stored at 2°C to 8°C. Check that the carton has been updated to reflect the 10-week refrigerated expiry date
  • Regardless of storage condition, orange cap vaccine should not be used after 12 months from the date of manufacture printed on the vial and cartons. Expiry dates based on 12 months from the date of manufacture are shown below. Expiry Information may be updated periodically, click here for updated expiry information.
    Printed Manufacturing Date 12-Month Expiry Date
    07/2021 30-Jun-2022
    08/2021 31-Jul-2022
    09/2021 31-Aug-2022
    10/2021 30-Sep-2022
    11/2021 31-Oct-2022
    12/2021 30-Nov-2022
    01/2022 31-Dec-2022
    02/2022 31-Jan-2023

Vial storage during use - Orange Cap1


Transportation of vials - Orange Cap1

If local redistribution is needed, vials may be transported at -90°C to -60°C (-130°F to -76°F) or 2°C to 8°C (35°F to 46°F). Thawed vials should never be refrozen.



Single-Use and Medium Thermal Shipping Containers5

The vaccine is provided in a Single-Use or Medium Thermal Shipping Container.

Single-Use Thermal Shipping Container

Single-Use Thermal Shipping Container

Ensure the label on the container states Single-Use ULT.

This container may NOT be used as temporary storage.

Please review the Shipping and Handling Guidelines for Single-Use Shipping Containers.

After use, dispose of the container at your facility. The Temperature-Monitoring Device must be returned to the supplier in the Pre-labeled Return Box to help Pfizer fulfill its commitment to reusable resources. Do not return vaccine or vaccine vials.

Click here to learn more about returning the thermal shipping container or temperature-monitoring device.

Medium Thermal Shipping Container

Medium Thermal Shipping Container

Ensure the label on the container states Medium ULT.

The vaccine is provided in a Medium Thermal Shipping Container. The thermal shipping container may be used as temporary storage for up to 30 days from delivery. Please refer to the storage and temperature guidelines available on this page.

If an ultra-low-temperature freezer is not available for storage, the thermal shipping container in which the vaccine arrives may be used as temporary storage for up to 30 days from delivery, when consistently re-filled with dry ice. Refer to the Dry Ice Replenishment Sheet . The thermal shipping container maintains a temperature range of -90°C to -60°C (-130°F to -76°F). Storage of the vials between -96°C to -60°C (-141°F to -76°F) is not considered an excursion from the recommended storage condition.3

Please review the Shipping and Handling Guidelines for Medium Thermal Shipping Containers.

Click here to learn more about returning the thermal shipping container or temperature-monitoring device.





Time and temperature considerations - Orange Cap5

  • Do not open vial cartons until there is a need to remove vials for transfer, thawing, or use
  • Upon delivery:
    • Inspect the thermal shipping container to confirm that ordered vial cartons were received
    • Do not stack or place anything on top of the thermal shipping container
  • Vial carton and vial handling between storage environments:
    • Once an individual vial is removed from a vial carton at room temperature, it should not be returned to frozen storage and should be thawed for use. Do not refreeze thawed vials

From ULT Freezer From ULT Freezer

  • Dry Ice can be hazardous. Take necessary precautions by reviewing the Dry Ice Safety Data Sheet, and consult with your Occupational Health Department. Ensure there is proper ventilation and wear safety goggles or safety glasses with side shields and waterproof insulated gloves when handling dry ice

Safely dispose - Orange Cap1,5

Discard vaccine vials that:

  • Have had the maximum number of complete doses extracted to administer vaccinations
  • Are more than 12 hours from time of dilution

Discard vaccine vials in a sharps container as medical waste to ensure they are permanently destroyed. Discard vial cartons as medical waste so they cannot be reused.

Safety and Storage Resources - Orange Cap

Safe Handling for Dry Ice
Safe Handling for Dry Ice
Dry Ice Safety Data Sheet
Dry Ice Safety Data Sheet
Product Safety Data Sheet
Product Safety Data Sheet - Pfizer-BioNTech COVID-19 Vaccine - Tris-Sucrose (applies to Gray Cap and Orange Cap)

Storage, Shipping, and Handling Resources - Orange Cap

Checklist for Storage, Handling, and Preparation
Checklist for Storage, Handling, and Preparation
Updated 07/20/2022
Return Instructions for Medium and Single-Use Thermal Shipping Containers
Learn more about returning the thermal shipping container or temperature-monitoring device
Updated 11/19/2021
Shipping and Handling Guidelines - Single-Use Thermal Shipping Container
Shipping and Handling Guidelines - Single-Use Thermal Shipping Container
Updated 01/24/2022
Shipping and Handling Guidelines - Single-Use Thermal Shipping Container
Shipping and Handling Guidelines - Medium Thermal Shipping Container
Updated 01/24/2022
Dry Ice Replenishment Sheet
Dry Ice Replenishment Sheet
Updated 11/05/2021

Ensuring the Authenticity of BioNTech and Pfizer's COVID-19 Vaccines

  • Pfizer is committed to patient safety and ensuring that people have accurate information about the vaccines, including how they are accessed and administered. We are actively monitoring for fraudulent offers of illegitimate vaccines to protect patients from products that might be dangerous and lead to serious and life-threatening harm
    • The vaccines are only administered intramuscularly by a healthcare professional1
    • The vaccines are not taken orally and are not available in a capsule or tablet form1
  • Authentic vaccines, manufactured by Pfizer Inc., will include the Pfizer and BioNTech names on the label and are dispensed in a vial as follows:
    • For 6 months through 4 years of age, DILUTE BEFORE USE, Maroon Cap vials, the vial label includes a maroon border446
    • For 5 through 11 years of age, DILUTE BEFORE USE, Orange Cap vials, the vial label includes an orange border15
    • For 12 years of age and older, DO NOT DILUTE, Gray Cap vials, the vial label includes a gray border34
    • For 12 years of age and older, DILUTE BEFORE USE, Purple Cap vials. Two versions of the vial label are in current circulation - with or without a purple border23
  • Ensure the safety of the vaccine vials by limiting access to only authorized personnel. The location they are stored in must be secure and locked when not in use.
    To prevent counterfeits, discard vaccine vials in sharps containers and empty vial cartons as medical waste or deface or safely crush all materials so they cannot be reused. Remember, the vaccines are only available through government-authorized vaccination centers – such as doctor’s offices, authorized pharmacies, outpatient clinics, community vaccination locations, and hospitals. The vaccines can only be administered by licensed healthcare professionals, or other individuals that are approved vaccinators, at government-authorized vaccination sites. Individual doses are not for sale6,78,128,128,99,13

If you suspect the vaccine you have purchased may be counterfeit, contact us at 1-800-438-1985 or visit https://www.pfizer.com/products/product-contact-information.

To learn more, visit https://www.pfizer.com/counterfeiting/frequently-asked-questions.


References
  1. Pfizer-BioNTech COVID-19 Vaccine. Emergency Use Authorization Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) (5 through 11 years of age), DILUTE BEFORE USE, Orange Cap. Pfizer and BioNTech; October 12, 2022.
  2. Pfizer-BioNTech COVID-19 Vaccine. Emergency Use Authorization Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) (12 years of age and older), DILUTE BEFORE USE, Purple Cap. Pfizer and BioNTech; October 18, 2022.
  3. Pfizer-BioNTech COVID-19 Vaccine. Emergency Use Authorization Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) (12 years of age and older), DO NOT DILUTE, Gray Cap. Pfizer and BioNTech; August 31, 2022.
  4. Pfizer-BioNTech COVID-19 Vaccine. Emergency Use Authorization Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) (6 months through 4 years of age), DILUTE BEFORE USE, Maroon Cap. Pfizer and BioNTech; August 31, 2022.
  5. Data on file. Pfizer Inc. New York, NY.
  6. COVID-19 Vaccination Program Interim Playbook for Jurisdiction Operations – September 16, 2020 Version 1.0. Centers for Disease Control and Prevention; 2020.
  7. McCurry MC. Secure disposal of vaccine vials and packaging recommendations. US Department of Defense; 2020.

Indication & Authorized Use

Indication & Authorized Use

Important Safety Information

MORE

Important Safety Information

MORE



Indication & Authorized Use


Authorized Use

Pfizer-BioNTech COVID-19 Vaccine is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 6 months of age and older.



Important Safety Information

Do not administer Pfizer-BioNTech COVID-19 Vaccine to individuals with known history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine.

Management of Acute Allergic Reactions

Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer-BioNTech COVID-19 Vaccine.

Monitor vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html).

Myocarditis and Pericarditis

Myocarditis and pericarditis have been reported following administration of Pfizer-BioNTech COVID-19 Vaccine.

Postmarketing data with authorized or approved monovalent mRNA COVID-19 vaccines demonstrate increased risks of myocarditis and pericarditis, particularly within the first week following receipt of the second primary series dose or first booster dose, with most booster doses likely administered at least 5 months after completing primary vaccination. For the Pfizer-BioNTech COVID-19 Vaccine, the observed risk is higher among adolescent males and adult males under 40 years of age than among females and older males, and the observed risk is highest in males 12 through 17 years of age. Although some cases required intensive care support, available data from short-term follow‑up suggest that most individuals have had resolution of symptoms with conservative management. Information is not yet available about potential long‑term sequelae. The CDC has published considerations related to myocarditis and pericarditis after vaccination, including for vaccination of individuals with a history of myocarditis or pericarditis (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html).

Syncope

Syncope (fainting) may occur in association with administration of injectable vaccines, in particular in adolescents. Procedures should be in place to avoid injury from fainting.

Altered Immunocompetence

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to Pfizer-BioNTech COVID-19 Vaccine.

Limitation of Effectiveness

Pfizer-BioNTech COVID-19 Vaccine may not protect all vaccine recipients.

Adverse Reactions

Primary Series Adverse Events:

In a clinical study (10 mcg modRNA) in children 5 through 11 years of age, adverse reactions following administration of any primary series dose included pain at the injection site (84.3%), fatigue (51.7%), headache (38.2%), injection site redness (26.4%), injection site swelling (20.4%), muscle pain (17.5%), chills (12.4%), fever (8.3%), joint pain (7.6%), lymphadenopathy (0.9%), nausea (0.4%), rash (0.3%), malaise (0.1%), and decreased appetite (0.1%).

Booster Dose Adverse Events:

In a clinical study (10 mcg modRNA) in children 5 through 11 years of age, adverse reactions following administration of a single booster dose were injection site pain (73.9%), fatigue (45.6%), headache (34.0%), muscle pain (18.3%), injection site swelling (16.4%), injection site redness (15.6%), chills (10.5%), fever (6.7%), joint pain (6.7%), diarrhea (4.9%), lymphadenopathy (2.5%), and vomiting (2.4%).

Post Authorization Experience

Severe allergic reactions, including anaphylaxis, and other hypersensitivity reactions (eg, rash, pruritus, urticaria, angioedema), diarrhea, vomiting, pain in extremity (arm), and syncope have been reported following administration of the Pfizer-BioNTech COVID-19 Vaccine.

Myocarditis and pericarditis have been reported following administration of Pfizer-BioNTech COVID-19 Vaccine.

Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of Pfizer-BioNTech COVID-19 Vaccine.

Before administration of Pfizer-BioNTech COVID-19 Vaccine, please click to see



For More Information

Medical Information Medical Information

Medical Information

Visit PfizerMedicalInformation.com
or call 1-800-438-1985

General Product Inquiries General Product Inquiries

General Product Inquiries

Call 1-877-829-2619

Shipment Support US Trade Customer Service Shipment Support US Trade Customer Service

Shipment Support
US Trade Customer Service

Call 1-800-666-7248

Pfizer Customer Service Pfizer Customer Service

Pfizer Customer Service

Call 1-800-879-3477

For More Information

Get COVID-19 vaccine info
texted directly to you

Enroll in the
BioNTech & Pfizer COVID Connect
text messaging program.

Get started
Medical Information Medical Information

Medical Information

Visit PfizerMedicalInformation.com
or call 1-800-438-1985

Shipment Support US Trade Customer Service Shipment Support US Trade Customer Service

Shipment Support
US Trade Customer Service

Call 1-800-666-7248

General Product Inquiries General Product Inquiries

General Product Inquiries

Call 1-877-829-2619

Pfizer Customer Service Pfizer Customer Service

Pfizer Customer Service

Call 1-800-879-3477

Medical Information Medical Information

Medical Information

Visit PfizerMedicalInformation.com
or call 1-800-438-1985

General Product Inquiries General Product Inquiries

General Product Inquiries

Call 1-877-829-2619

Shipment Support US Trade Customer Service Shipment Support US Trade Customer Service

Shipment Support
US Trade Customer Service

Call 1-800-666-7248

Pfizer Customer Service Pfizer Customer Service

Pfizer Customer Service

Call 1-800-879-3477

Scroll down to continue